1 Min Read
Nov 6 (Reuters) - Amgen Inc:
* Announces new analyses of high-risk patient subgroups from Repatha (evolocumab) cardiovascular outcomes study at AHA Scientific Sessions 2017 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.